Study Finds Sleep Factors Offer Little Insight into Dementia Risk

Recent research published in Ageing International reveals that sleep disturbances and the medications used to treat them may not significantly predict cognitive decline in older adults. The study, led by Lydia Ann and Constance H. Fung, examined whether variables like insomnia severity, dosage of sleep medications, and obstructive sleep apnea risk could enhance dementia risk assessments when combined with established factors.

Research Background

The motivation for this study is based on a growing concern about cognitive impairment in the aging population. According to projections, the number of individuals affected by dementia is set to increase from 55 million in 2019 to an astounding 139 million by 2050. The Lancet Commission’s recent update highlights numerous modifiable risk factors including low education, high cholesterol, and social isolation, leaving sleep-related issues as a possible contributor to cognitive decline.

Study Design and Findings

This study involved 348 participants recruited from Veterans Affairs and an academic site, all taking at least one benzodiazepine or z-drug such as clonazepam or zolpidem. The average age of the participants was around 68.8 years, with a diverse educational background.

The researchers assessed how factors like insomnia severity and hypnotic dosage correlated with performance on standard cognitive tests. However, their findings were somewhat surprising. The analysis revealed that none of the sleep-related factors notably improved the predictive capacity of dementia risk models, which already included key variables like age, education, and vascular risks.

Results Overview

The results showed no significant shifts when sleep-related variables were added to standard dementia risk models. For example:

• The base model accounted for 13.9% of variance in scores on the Mini-Mental State Examination (MMSE).
• When sleep factors were incorporated, this increased only to 14.2%.
• Similar patterns were observed for other cognitive tests, indicating that the sleep variables did not provide any significant additional explanatory power.

Across different assessments, every test returned values indicating minimal contribution from sleep-related aspects.

Implications of the Study

The researchers caution against viewing these results as a dismissal of sleep’s role in cognitive performance. Instead, they suggest that sleep issues might overlap significantly with the conventional dementia risk factors included in the model, reducing their independent explanatory capacity. Moreover, the population studied generally exhibited cognitive stability, limiting the range for detecting variations.

It is also important to note that this is the first known study to systematically assess the incremental contributions of sleep disturbances relative to other dementia risk factors in a concurrently analyzed manner.

Limitations and Future Directions

While the findings are intriguing, there are limitations to consider. The study exclusively examined individuals already using sleep medications and suffered from a lack of adherence data for obstructive sleep apnea treatment. Furthermore, the commonly used MMSE may not be as sensitive as other cognitive assessment tools.

The authors recommend further investigations comparing individuals both on and off sleep medications, particularly in diverse cognitive cohorts. A focus on younger patients, especially those with mild cognitive impairments, may reveal more discernible effects of sleep on cognitive function.

In summary, while dementia risk factors carry the majority of predictive weight in this cohort of older adults using sleep medications, the role of sleep variables remains an area worthy of further exploration.